FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Special Prosecutor Alleges Yoon Suk Yeol Sought North Korea Provocation to Justify Martial Law 
Tunisia Protests Grow as Opposition Unites Against President Kais Saied’s Rule 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Preservation Group Sues Trump Administration to Halt $300 Million White House Ballroom Project 
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Jimmy Lai Convicted Under Hong Kong National Security Law in Landmark Case 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Rite Aid has sued the U.S. Department of Justice (DOJ) to halt a lawsuit alleging the company's involvement in illegally filling prescriptions for addictive opioid medications. The lawsuit comes as Rite Aid finds itself in a bankruptcy situation.
Reuters reported that the DOJ's position threatens to impede the ongoing restructuring efforts by the company. In response, Rite Aid has requested the U.S. Bankruptcy Judge Michael Kaplan will rule that the DOJ lawsuit should not proceed while the company is under bankruptcy protection.
DOJ's Lawsuit Pause and Rite Aid's Request for Equal Treatment
The DOJ had initially filed the lawsuit against Rite Aid in March, and despite Rite Aid's bankruptcy filing, it agreed to a "brief pause" of the lawsuit, according to PennLive. However, Rite Aid argues that this stance undermines its restructuring efforts.
Rite Aid seeks to put the government on equal footing with other opioid-related plaintiffs whose lawsuits were automatically halted due to the company's bankruptcy filing. The DOJ maintains that its lawsuit is not affected by the bankruptcy filing as it exercises its "police powers" through legal action.
Rite Aid, which operates approximately 2,000 retail pharmacies across 17 U.S. states, filed for bankruptcy protection in October. It aims to close underperforming stores and address over 1,600 lawsuits surrounding allegations of over-selling addictive opioid medications by filling illegal or suspicious prescriptions. However, a court-appointed committee representing opioid plaintiffs has expressed concerns over potential non-payment to victims harmed by Rite Aid's alleged reckless sale of opioid drugs.
Rite Aid's Legal Battle Implications
As Rite Aid fights the DOJ's lawsuit, the outcome will have far-reaching implications. It will determine whether the company can proceed with its restructuring efforts unhampered by legal actions, and if the DOJ's exercise of "police powers" can continue despite Rite Aid's bankruptcy status.
Additionally, the opioid creditors and victims affected by the company's alleged actions will closely monitor the proceedings, hoping for equitable resolutions.
Attorney Arik Preiss, representing opioid creditors, raised concerns that Rite Aid's bankruptcy proceedings seem to prioritize its top lenders over other stakeholders, potentially putting them at odds with the DOJ.
Rite Aid's major competitors, including Walgreens, Walmart, and CVS, have already agreed to settle a series of similar opioid lawsuits outside of bankruptcy, amounting to $13.8 billion.
The DOJ's opposition to opioid settlements in the bankruptcies of Endo International and Purdue Pharma has complicated those cases as well, delaying proposed settlements and drawing appeals to higher courts.
Photo: Rite Aid Newsroom
